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Perioperative anaemia increases postoperative morbidity and  mortality1. Up to 75% of patients present with 
anaemia before  surgery2. Iron deficiency, secondary to intraoperative blood loss and increased iron requirements, 
is the leading cause of anaemia in surgical  patients3, 4. Identification of preoperative anaemia and iron deficiency 
has been recommended for all those with anticipated moderate to high (> 500 mL) surgical blood  loss5, 6.
Bimaxillary orthognathic surgery is performed for correction of facial abnormalities, such as prognathism, 
retrognathism, and facial  asymmetry7. Because of high vascularity and poor visualisation of the surgical site, 
this surgery is accompanied by a substantial likelihood of excessive blood loss and the potential need for blood 
 transfusion8, 9. Preoperative autologous blood donation and hypotensive anaesthesia are often used to reduce 
the need for allogenic transfusion with bimaxillary orthognathic  surgery10, but preoperative autologous blood 
donation has several drawbacks. The donation process can be uncomfortable for the patient, it can lead to anae-
mia, and its cost is relatively high.
Preoperative intravenous (IV) iron has been demonstrated to reduce transfusion requirements and increase 
postoperative haemoglobin (Hb)  levels11–16. Furthermore, there are a number of trials reporting on the improved 
erythropoietic function (increased reticulocyte count) using preoperative IV  iron11, 17, 18. However, administration 
of preoperative IV iron is not always feasible, especially in emergency surgery. Infusing iron intraoperatively is 
more convenient, but data regarding the effectiveness of this approach are  inadequate19. We thereby conducted 
a randomised controlled trial to evaluate the effects of intraoperative IV iron on postoperative Hb levels and 
transfusion requirements in patients undergoing bimaxillary orthognathic surgery.
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Methods
Patients.  The Severance Hospital Institutional Review Board (Yonsei University Health System, Seoul, 
Republic of Korea, Chairperson Professor Seung Min Kim) approved the study protocol on 17 February 2017 
(No. 4-2016-1146), which is registered at ClinicalTrials.gov (No. NCT03094182, 29/03/17). This study was per-
formed in accordance with the Declaration of Helsinki. All participants provided written informed consent 
before randomisation. We enrolled 57 adults (aged 19–40 years) who underwent elective bimaxillary orthog-
nathic surgery between September 2017 and March 2019 by one surgeon (Y-S.J.). The American Society of Anes-
thesiologists (ASA) physical status class of all subjects was I. The exclusion criteria were pregnancy, haemato-
logic disease, kidney-related anaemia, hepatitis, severe atopy, or drug allergies. None received iron supplements. 
The preoperative autologous blood donation was performed 2 weeks prior to surgery.
Randomisation and interventions.  Participants were assigned at random to one of two groups—iron 
group (n = 28) or control group (n = 29)—using a computer-generated randomisation table (available at https 
://www.rando m.org). An anaesthesiologist not involved in data collection conducted the randomisation and 
group assignments. The iron group received 1000 mg ferric derisomaltose (Monofer, 200 mg/2 mL, Solupharm, 
Melsungen, Germany), which was added to normal saline to generate a total volume of 100 mL. This solution 
was infused over 30 min after anaesthesia induction. The same volume of normal saline was administered in an 
identical manner to the control group. An anaesthesiologist not involved in data collection prepared the two 
solutions. The investigator, surgeons, and study participants were blinded to the group assignment.
Anaesthesia.  Anaesthesia was induced with 2 mg kg−1 propofol (Fresofol MCT 1%, Fresenius Kabi Korea 
Ltd, Seoul, Korea) and 0.5–1 µg kg−1 remifentanil (Ultiva, GlaxoSmithKline Korea, Seoul, Korea). Tracheal intu-
bation was facilitated with 1.0 mg kg−1 rocuronium (Esmeron, MSD Korea Ltd, Seoul, Korea). After intubation, 
a radial artery catheter and an additional peripheral venous line were inserted. Anaesthesia was maintained 
with sevoflurane in 40%  O2 and remifentanil infused at 0.05–0.15 µg kg−1 min−1. Controlled hypotension, with a 
systolic blood pressure < 100 mmHg, was used during maxillary manipulation. Red blood cells were transfused 
when the Hb fell below 8.5 g/dL.
Data collection and outcome assessments.  The primary outcome was the postoperative blood Hb 
level. Secondary outcomes included reticulocyte count, and reticulocyte production index, serum levels of iron, 
ferritin, transferrin, transferrin saturation, and total iron binding capacity (TIBC), and perioperative blood 
transfusion requirements. Reticulocyte production index was the reticulocyte percentage corrected for both 
the haematocrit and reticulocyte  lifespan20. The reticulocyte count and reticulocyte percentage were measured 
automatically using the ADVIA 2120i analyser (Siemens Healthcare, Erlangen, Germany). All laboratory values 
were obtained before surgery and at 1 day, 2 weeks, and 4 weeks postoperatively.
Statistical analysis.  The sample size was calculated for the primary outcome (postoperative Hb). An Hb 
difference of > 0.8 mg/dL between iron and control groups was considered clinically  relevant11. Twenty-six sub-
jects were required in each group for a power of 80% at a significance level of 5%. To account for 10% dropout, 
we enrolled 29 in each group.
Demographic and intraoperative data are presented as number of patients, mean ± standard deviation, or 
median (interquartile range). Haematologic and iron parameters are expressed as estimated mean ± standard 
error values obtained from a linear mixed model. For continuous variables, the independent t-test was used to 
compare parametric data, and the Mann–Whitney U test was used for nonparametric data. The χ2 or Fisher’s 
exact test was used to evaluate categorical variables. Linear mixed models of fixed and random effects between 
groups were used to examine repeated measurements of haematologic and iron parameters. Intergroup compari-
sons of parameter changes over time included group-by-time interactions. Correlations between repeated meas-
ures were examined using an unstructured covariance matrix. Post hoc analysis was performed with Bonferroni 
correction to adjust for multiple comparisons. P values < 0.05 were considered statistically significant. Statistical 
analyses were conducted using SPSS 25.0 (IBM Corp., Armonk, NY, USA), R version 3.5.1 (R Foundation for 
Statistical Computing, Vienna, Austria), and SAS 9.4 (SAS Inc., Cary, NC, USA).
Results
Of the 58 subjects evaluated for eligibility, 57 were enrolled and assigned either to the iron (n = 28) or control 
group (n = 29) (Fig. 1). One subject was excluded due to allergic reaction to antibiotics in pre-anaesthesia room 
after informed consent. The remaining participants completed the study. As shown in Table 1, patient charac-
teristics and intraoperative variables were not significantly different between groups. Before surgery, 26 patients 
(male:female, 4:22) had iron deficiency (serum ferritin < 30 µg/L) and 10 (male:female, 1:9) had a transferrin 
saturation of < 20% and serum ferritin of < 100 µg/L. Requirements of blood transfusion perioperatively did not 
differ significantly between groups: one (4%) individual in the iron group and three (10%) in the control group 
(P = 0.630).
At 2 weeks postoperatively, the Hb was higher in the iron group than in the control group but there was no 
statistical difference after adjustment for multiple testing (12.9 g/dL vs. 12.2 g/dL, P = 0.108) (Table 2). The reticu-
locyte count was higher in the iron group than in the control group at 4 weeks (95.1 × 103/µ L vs. 66.8 × 103/µ L, 
P = 0.045) after surgery. Corroborating these observations, the reticulocyte production index at 2 weeks postop-
eratively was higher in the iron group than in the control group (1.51 vs. 1.10, P = 0.018) (Fig. 2).
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Both serum iron and transferrin saturation were higher in the iron group than in the control group at 1 day 
and 2 weeks postoperatively but were similar in the two groups at 4 weeks after surgery (Table 3). Serum fer-
ritin was higher in the iron group than in the control group at 2 weeks and 4 weeks after surgery. As expected, 
TIBC and transferrin levels were higher in the control group than in the iron group at 2 weeks and 4 weeks 
postoperatively.
The linear mixed model revealed that there were statistically significant between-group differences in changes 
in reticulocyte count, reticulocyte production index, iron, ferritin, transferrin saturation, TIBC, and transferrin 
during the 4 weeks following surgery (Table 4).
No surgical complication or adverse reaction related to IV iron was observed. Postoperative hospital length 
of stay did not differ between the groups (3 days vs. 3 days, P = 0.326).
Figure 1.  Flow diagram of the study.
Table 1.  Patient characteristics and intraoperative data. Values are presented as median (interquartile range), 
mean ± standard deviation, or number of patients.
Control group (n = 29) Iron group (n = 28) P value
Age (years) 23 (20–26) 22 (20–25) 0.681
Gender (male/female) 13/16 14/14 0.900
Height (cm) 168.5 ± 6.2 168.6 ± 7.3 0.957
Weight (kg) 61.0 (55.0–68.0) 59.5 (53.5–70.5) 0.661
Diagnosis 0.648
Apertognathia 0 1 (4)
Facial asymmetry 15 (52) 12 (43)
Prognathism 13 (45) 13 (46)
Retrognathism 1 (3) 2 (7)
Ferritin < 30 μg/L 12 (41) 14 (50) 0.514
Transferrin saturation < 20% 5 (17) 5 (18)  > 0.999
Operation time (min) 203 ± 37 211 ± 36 0.398
Anaesthesia time (min) 248 ± 38 251 ± 39 0.707
Intraoperative fluid intake (mL) 1935 ± 546 1863 ±636 0.645
Intraoperative bleeding (mL) 500 (300–650) 450 (325–700) 0.835
Patients required transfusion (n, %) 3 (10) 1 (4) 0.630
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Table 2.  Haematologic parameters. Values are presented as estimated mean ± standard error from linear 
mixed model. POD postoperative day. Adjusted P value indicates the Bonferroni-corrected P-value.
Control group (n = 29) Iron group (n = 28) Adjusted P value
Haemoglobin base (g/dL) 12.0 ± 0.3 12.3 ± 0.3 0.990
POD1 10.8 ± 0.3 10.8 ± 0.3  > 0.999
2 weeks 12.2 ± 0.3 12.9 ± 0.3 0.108
4 weeks 12.7 ± 0.3 13.4 ± 0.4 0.408
Reticulocyte count base (103/µL) 92.0 ± 4.8 86.3 ± 5.0  > 0.999
POD1 89.9 ± 4.7 86.0 ± 5.0  > 0.999
2 weeks 86.5 ± 4.9 105.6 ± 5.4 0.105
4 weeks 66.8 ± 6.8 95.1 ± 10.1 0.045
Reticulocyte production index base (%) 1.33 ± 0.09 1.15 ± 0.09 0.282
POD1 1.09 ± 0.09 1.01 ± 0.09  > 0.999
2 weeks 1.10 ± 0.09 1.51 ± 0.10 0.018
4 weeks 1.07 ± 0.14 1.55 ± 0.25 0.459
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Discussion
In this randomised clinical trial, intraoperative administration of IV iron maintained Hb in the postoperative 
period by increasing haematopoiesis and iron bioavailability.
Patient blood management (PBM) is a multidisciplinary concept that focuses on patient safety by minimising 
blood loss and optimising physiological tolerance of  anaemia21. Iron is necessary for erythroid cell proliferation, 
in addition to Hb synthesis, as it functions as a cofactor for several enzymes, such as DNA replicases, DNA poly-
merases, and DNA  helicases22. These enzymes are necessary for cell division of all cells, including haematopoietic 
stem cells necessary for  erythropoiesis23. Because iron is an essential component of red blood cell production, 
management of iron reserves during the perioperative period is important. However, surgically induced inflam-
matory responses upregulate hepcidin synthesis, and hepcidin decreases iron bioavailability by inhibiting iron 
absorption from the gastrointestinal tract and preventing the release of stored  iron24. These effects lead to hypo-
ferremia and iron-restricted erythropoiesis, even when iron stores are  normal25. IV iron provides a readily avail-
able source of  iron25, creating a five-fold erythropoietic response to anaemia resulting from blood  loss26. Besides 
preoperative anaemia management, there are many perioperative care and alternative PBM strategies, including 
antifibrinolytics (tranexamic acid), intraoperative autologous cell salvage, anaesthetic management (autologous 
normovolemic haemodilution, controlled hypotension, normothermia), reduced phlebotomy blood loss (smaller 
tubes, eliminate unnecessary testing), and point-of-care coagulation monitoring (thromboelastography)27, 28.
Low serum ferritin level before IV iron and transferrin saturation were the useful parameters of iron stores 
within the body. Serum ferritin < 30 µg/L alone, or < 100 µg/L in the presence of serum transferrin satura-
tion < 20%, indicated iron  deficiency5. Serum ferritin < 100 µg/L or transferrin saturation < 20% was recommended 
Table 3.  Iron parameters. Values are presented as estimated mean ± standard error from linear mixed model. 
TIBC total iron binding capacity. Adjusted P value indicates the Bonferroni-corrected P-value.
Control group (n = 29) Iron group (n = 28) Adjusted P value
Iron base (µg/dL) 104.0 ± 25.7 92.1 ± 25.7  > 0.885
POD1 31.8 ± 17.9 605.3 ± 25.7  < 0.001
2 weeks 55.9 ± 26.2 83.0 ± 28.4  < 0.001
4 weeks 73.0 ± 39.2 77.0 ± 22.1  > 0.999
Ferritin base (μg/L) 46.1 ± 19.8 57.9 ± 19.9  > 0.999
POD1 63.6 ± 29.8 101.1 ± 27.9 0.075
2 weeks 57.4 ± 23.0 495.2 ± 26.2  < 0.001
4 weeks 30.9 ± 27.6 276.7 ± 38.4  < 0.001
Transferrin saturation base (%) 39.0 ± 2.55 34.2 ± 2.60  > 0.777
POD1 14.9 ± 4.43 80.6 ± 4.02  < 0.001
2 weeks 18.4 ± 3.16 31.8 ± 3.71  < 0.001
4 weeks 19.7 ± 4.02 27.0 ± 5.92 0.459
TIBC base (μg/dL) 271.7 ± 12.6 273.3 ± 12.8  > 0.999
POD1 275.7 ± 22.2 838.6 ± 20.1  < 0.001
2 weeks 325.7 ± 15.7 264.0 ± 18.5  < 0.001
4 weeks 342.3 ± 20.1 266.5 ± 29.8  < 0.001
Transferrin base (mg/dL) 220.6 ± 6.25 222.4 ± 6.42  > 0.999
POD1 227.8 ± 9.10 213.3 ± 8.92  > 0.999
2 weeks 267.1 ± 7.17 223.0 ± 8.15  < 0.001
4 weeks 284.9 ± 8.47 219.2 ± 11.7  < 0.001
Table 4.  Relative change in iron-related blood parameters in the 4 weeks following surgery in the iron group 
compared to the control group, assessed using a linear mixed model. TIBC total iron binding capacity.
Parameter PGroup×Time
Haemoglobin (g/dL) 0.102
Reticulocyte count  (103/µL) 0.002
Reticulocyte production index (%) 0.002
Iron ( µg/dL)  < 0.001
Ferritin (μ/L)  < 0.001
Transferrin saturation (%)  < 0.001
TIBC ( µg/dL)  < 0.001
Transferrin (mg/dL)  < 0.001
6
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15853  | https://doi.org/10.1038/s41598-020-72827-5
www.nature.com/scientificreports/
to detect the iron deficiency in patients with chronic heart failure, chronic kidney disease, and inflammatory 
bowel  disease29. A preoperative ferritin < 100 μg/L may indicate insufficient iron stores to recover from a 3–4 g/
dL decrease in Hb  decrease5. Treating preoperative iron deficiency can decrease the need for perioperative 
blood transfusion and consequently improve  outcomes12, 30. However, the presence of iron deficiency is often 
not evaluated before surgery in healthy patients. Unexpectedly, 91% of subjects in our study had inadequate 
iron stores for moderate to high blood loss surgery, as evidenced by a serum ferritin < 100 µg/L preoperatively. 
Females were especially affected: 73% had a serum ferritin < 30 µg/L, and 90% had a serum ferritin < 100 µg/L 
plus transferrin saturation < 20% preoperatively. Of note, these subjects were all healthy (ASA class 1), but they 
did not have adequate iron stores for moderate blood loss surgery.
In cases with inadequate iron stores or iron deficiency but not anaemia, iron supplementation before surgery 
with an anticipated blood loss of > 500 mL might be  beneficial4. Preoperative assessment and treatment of iron 
deficiency may be particularly important in women. Because of their lower blood volume, women have higher 
transfusion rates than males, when undergoing the same type of  surgery31. Females with a preoperative Hb of 
12 g/dL are two times more likely to receive a blood transfusion than males with an Hb of 13 g/dL5.
A high reticulocyte count after surgery reflects an increased erythropoietic response to blood  loss11. Reticu-
locyte production index is used to assess whether the bone marrow is responding appropriately to the presence 
of  anaemia20. The reticulocyte count and reticulocyte production index were higher in the iron group than in 
the control group at 2 weeks and 4 weeks after surgery, indicating that the intraoperative IV iron increased 
haematopoietic activity.
During progressive iron depletion, laboratory results typically show reduced serum ferritin and iron levels 
and increased serum transferrin and TIBC  values20. These findings were evident in the control group at 2 weeks 
postoperatively, as expected, but not in the iron group. IV iron has been previously shown to improve iron bio-
chemical outcomes and haematopoietic response to severe anaemia and provide long-term normalisation of Hb 
 levels32. Prior studies reported that IV iron administered 2 to 4 weeks before surgery decreased perioperative red 
blood cell transfusion rates and hospital length of  stay14. Furthermore, IV iron administration less than 1 week 
preoperatively has been associated with improved  outcomes11, 16. However, iron supplementation is not always 
administered before surgery, and unexpected bleeding may occur during the operation. In these situations, 
intraoperative iron supplementation appears to be a good alternative, as our results showed that, in the absence 
of iron supplementation before surgery, intraoperative IV iron promoted haematopoiesis and iron bioavailability.
This study has some limitations. We included only healthy subjects; thus, the effects of intraoperative IV iron 
in patients with chronic disease remain unknown. We excluded candidates with anaemia due to kidney disease 
because they had a decreased ability of erythropoietin production and the error between subjects could be  large33. 
Healthy people have a good haematopoietic response to blood loss, which can underestimate the effect of intra-
venous iron. In patients whose iron availability is inhibited by chronic inflammation, intravenous iron facilitates 
the rapid replenishment of available iron and Hb levels, resulting in a greater haematopoietic effect than that in 
healthy  individuals29. Although previous research suggested that supplemental iron improved markers of iron 
status and anaemia in patients with chronic disease and older  persons15, 34–36, investigations of intraoperative 
iron use in this patient population should be done separately. Another potential limitation of our study was that 
the amount of bleeding during surgery was less than expected. However, because decreases in Hb are greater 
with larger volumes of blood loss, the postoperative difference in Hb levels between groups may have been even 
larger if blood loss was as high as anticipated. Lastly, we started administering intravenous iron immediately 
after induction to give it before the start of surgery. A certain amount of iron might be lost due to intraoperative 
bleeding. However, the results showed that iron parameters are not significantly affected by intraoperative blood 
loss. The preoperative anaemia or iron deficiency assessment has not been performed in some patients with a 
high risk of developing postoperative anaemia undergoing major surgery. In this case, even after anaesthesia, 
administration of iron before starting surgery would be effective for haematopoiesis based on our study.
In conclusion, intraoperative administration of IV iron maintains postoperative Hb values in patients under-
going bimaxillary orthognathic surgery by increasing iron bioavailability and haematopoiesis. Thus, intraop-
erative IV iron appears to be a useful strategy for blood management in patients undergoing operations with 
anticipated moderate to high blood loss.
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